GD2+ cancer stem cells in triple-negative breast cancer: mechanisms of resistance to breast cancer therapies

Cancer Drug Resist. 2022 Jun 22;5(3):721-726. doi: 10.20517/cdr.2022.30. eCollection 2022.

Abstract

Research has led to the development of tailored treatment options for different cancers in different patients. Despite some treatments being able to provide remarkable responses, nearly all current treatments encounter the same issue: resistance. Here, we discuss our experiences with how breast cancers resist therapies. The focus of our discussion revolves around the cancer stem cell subpopulation and their mechanisms for resistance.

Keywords: Drug resistance; breast cancer therapy; cancer stem cells; triple-negative breast cancer.